Evidence map›Paper›PMID 27405732›Full record

Trial reportJournal of cancer survivorship : research and practice2017

Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208.

Carol M Moinpour, Joseph M Unger, Patricia A Ganz, Alice B Kornblith, Ellen R Gaynor, Mindy Ann Bowers, Gretchen S Gatti, Mark S Kaminski, Harry Paul Erba, Ting Wang and 3 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cancer survivorship : research and practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Carol M MoinpourPublic Health Sciences Division, SWOG Statistical Center, Fred Hutchinson Cancer Research Center, M3-C102/P.O. Box 19024, 1100 Fairview Avenue North, Seattle, WA, 98109-1024, USA. cmoinpou@fredhutch.org.
Joseph M UngerPublic Health Sciences Division, SWOG Statistical Center, Fred Hutchinson Cancer Research Center, M3-C102/P.O. Box 19024, 1100 Fairview Avenue North, Seattle, WA, 98109-1024, USA.
Patricia A GanzUCLA Fielding School of Public Health, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.
Alice B Kornblith, 140 8th Ave, Apt4-O, Brooklyn, NY, USA.
Ellen R GaynorStritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University, Maywood, IL, USA.
Mindy Ann BowersDivision of Nephrology, Nephrology Clinical Trials Unit, The Ohio State University, Columbus, OH, USA.
Gretchen S GattiMark H. Zangmeister Center, Columbus CCOP, Columbus, OH, USA.
Mark S KaminskiDepartment of Internal Medicine, Division of Hematology/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.
Harry Paul ErbaDivision of Hematology/Oncology, The Kirklin Clinic-Birmingham, Birmingham, AL, USA.
Ting WangEducational Psychology Dept. (PhD program), College of Education, University of Washington, Seattle, WA, USA.
Jihye YoonPublic Health Sciences Division, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA.
Oliver W PressFred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA.
Richard I FisherFox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA, USA.

Funding

SWOG Foreign AccrualsU10CA037429 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BLANKE, CHARLES D., MEYSKENS, FRANK L. · 1985 to 2014
$205.2M
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · 2014 to 2026
$152.1M
SWOG - Foreign Accrual under UMiU10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BLANKE, CHARLES D. · 1985 to 2013
$141.3M
SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Catherine M. Tangen · 2014 to 2026
$115.2M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
SOUTHWEST ONCOLOGY GROUP--STATISTICAL CENTERU10CA038926 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LEBLANC, MICHAEL L. · 1985 to 2013
$69.8M
Heartland Cancer Research NCORPUG1CA189830 · NCI · DECATUR MEMORIAL HOSPITAL · PI Bryan A. Faller · 2014 to 2026
$40.9M
The Pacific Cancer Research Consortium (PCRC), an NCORP Community SiteUG1CA189953 · NCI · SWEDISH MEDICAL CENTER, FIRST HILL · PI Alison Katherine Conlin, Charles Drescher · 2014 to 2026
$27.4M
Gulf South Minority/Underserved Clinical Trials Network (Gulf South M/U CTN)UG1CA189854 · NCI · LSU HEALTH SCIENCES CENTER · PI AUGUSTO C. OCHOA · 2014 to 2026
$27.1M
UPSTATE CAROLINA COMMUNITY CLINICAL ONCOLOGY PROGRAMU10CA035119 · NCI · SPARTANBURG REGIONAL MEDICAL CENTER · PI BEARDEN, JAMES D · 1985 to 2013
$21.5M
The Hawaii NCORPUG1CA189804 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI Jared Acoba, Jeffrey Lee Berenberg · 2014 to 2026
$15.7M
NCI NIH HHS N01 CA013612NCI NIH HHS N01 CA032102NCI NIH HHS N01 CA035119NCI NIH HHS N01 CA038926NCI NIH HHS U10 CA012644NCI NIH HHS U10 CA013612NCI NIH HHS U10 CA016385NCI NIH HHS U10 CA022433NCI NIH HHS U10 CA032102NCI NIH HHS U10 CA035119NCI NIH HHS U10 CA035128NCI NIH HHS U10 CA035262NCI NIH HHS U10 CA037429NCI NIH HHS U10 CA037981NCI NIH HHS U10 CA038926NCI NIH HHS U10 CA046113NCI NIH HHS U10 CA046282NCI NIH HHS U10 CA046368NCI NIH HHS U10 CA052654NCI NIH HHS U10 CA058348NCI NIH HHS U10 CA074647NCI NIH HHS U10 CA076447NCI NIH HHS U10 CA180801NCI NIH HHS U10 CA180818NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180828NCI NIH HHS U10 CA180834NCI NIH HHS U10 CA180835NCI NIH HHS U10 CA180855NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA189804NCI NIH HHS UG1 CA189808NCI NIH HHS UG1 CA189830NCI NIH HHS UG1 CA189853NCI NIH HHS UG1 CA189854NCI NIH HHS UG1 CA189872NCI NIH HHS UG1 CA189952NCI NIH HHS UG1 CA189953NCI NIH HHS UG1 CA189954NCI NIH HHS UG1 CA189957NCI NIH HHS UG1 CA189974
6 · The paper itself

Abstract

purposeWe describe 7 years of follow-up for the energy/vitality outcome in early-stage Hodgkin's disease patients treated on a randomized clinical trial that compared subtotal lymphoid irradiation (STLI) with combined modality treatment (CMT) (SWOG 9133). Survivorship research questions involved the extent to which symptoms/side effects endured over a follow-up period of 7 years for this early-stage patient group.

methodsTwo hundred thirty-nine patients participated in the quality of life (QOL) companion study (SWOG 9208) and completed the SF-36 vitality scale, SF-36 health perception item, Cancer Rehabilitation Evaluation System-Short Form (CARES-SF), and symptom distress scale. This paper reports vitality outcome results obtained from randomization, 6 months, and annually for 7 years. To assess changes in vitality over time, we used linear mixed models with patient as a random effect.

resultsPatients receiving CMT had lower observed vitality at 6 months than did the STLI patients (p < .0001). However, beginning at year 1, vitality results did not differ significantly by treatment over the 5-year (p = .13) and 7-year (p = .16) follow-up periods. Vitality only slightly improved over baseline in either group after treatment. The results were similar after accounting for patterns of recurrence and missing data.

conclusionsThis study demonstrated that patients with early-stage Hodgkin's disease experience a short-term (at 6 months) decrease in vitality with treatment, which is more severe with CMT, but that after the first year, vitality scores were similar between the two treatment groups. Enduring fatigue results for patients receiving these therapies were not observed. Implications for cancer survivors These data provide comprehensive 7-year follow-up vitality information, an important symptom for early-stage lymphoma survivors.

Indexed as

AdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleFollow-Up StudiesHodgkin DiseaseHumansLymphatic IrradiationMaleMiddle AgedQuality of LifeSurvivorsTreatment OutcomeYoung AdultCombined modality treatmentHodgkin’s diseaseQuality of lifeSymptomsVitality

Identifiers

PMID27405732
PMCPMC5233644

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.